Beyond the PI3K/AKT core, network pharmacology analysis uncovered 185 overlapping targets, including inflammatory regulators NFKB1 and RELA [30], suggesting that cinnamic acid may enhance its anti-liver cancer effect by inhibiting the tumor-associated inflammatory microenvironment. The gene discussed is NFKB1; the disease is neoplasm.